Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 7,874,000	$ 14,602,000
Prepaid expenses and other current assets	1,253,000	1,045,000
Total current assets	9,127,000	15,647,000
Long-term assets
Property and equipment, net	22,000	26,000
Operating lease right-of-use assets	53,000	131,000
Intangible assets, net	10,207,000	10,693,000
Other long-term assets	126,000
Total assets	19,535,000	26,497,000
Current liabilities
Accounts payable	2,778,000	1,777,000
Accrued compensation	721,000	1,675,000
Accrued clinical trial site costs	3,531,000	3,222,000
Operating lease liabilities	39,000	155,000
Other current liabilities	692,000	484,000
Total current liabilities	7,761,000	7,313,000
Long-term liabilities
Contingent liability for Essentialis purchase price	9,134,000	8,835,000
Total liabilities	16,896,000	16,149,000
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 8,168,788 and 8,159,382 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	8,000	8,000
Additional paid-in-capital	248,393,000	247,762,000
Accumulated deficit	(245,778,000)	(237,422,000)
Accumulated other comprehensive income	16,000
Total stockholders’ equity	2,639,000	10,348,000
Total liabilities and stockholders’ equity	19,535,000	26,497,000
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 1,000	$ 1,000